Foundation date



#Biotechnology - Therapeutics


eTheRNA BVBA is a spin-off company from VUB. The company was created in 2013 by Prof. Kris Thielemans out of the Laboratory of Molecular and Cellular Therapy (LMCT). eTheRNA is currently focused on the manufacturing of mRNA based drugs/vaccines to support clinical development and diagnostic applications. The aim is to grow into a Flanders based biopharma company that will develop a leadership position in not only mRNA manufacturing but also developing mRNA based drugs that enhance the immunological response against certain targeted diseases/indications.

Upcoming events

News by eTheRNA

  • eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A

    Tuesday July 27th 2021

  • eTheRNA immunotherapies and Ghent University announce mRNA Delivery Collaboration and License Agreement

    Tuesday July 13th 2021

  • eTheRNA immunotherapies and Quantoom Biosciences announce a strategic collaboration for the development of a novel RNA production system

    Tuesday June 29th 2021